A combination therapy of whole lung lavage and GM-CSF inhalation in pulmonary alveolar proteinosis.

Abstract

Systemic and inhalation therapy of granulocyte-macrophage colony-stimulating factor (GM-CSF) is usually effective in controlling autoimmune pulmonary alveolar proteinosis (PAP), but some cases are refractory to GM-CSF therapy and subjected to whole lung lavage (WLL). A 9-year-old girl developed severe respiratory failure due to autoimmune PAP was treated with inhalational 250 microg of GM-CSF daily, however, it was ineffective. Unilateral WLL was performed three times and subsequent GM-CSF inhalation therapy yielded marked physiological and radiological improvement and was continued for 1 year.

• Authors: Hajime Yamamoto, Etsuro Yamaguchi, Hiroatsu Agata, Nobuhisa Kandatsu, Toru Komatsu, Seiko Kawai, Kenji Baba, Tomonari Awaya, Ryuta Nishikomori, Masahito Tsurusawa, Koh Nakata
• Journal: Pediatric pulmonology (Pediatr Pulmonol) Vol. 43 Issue 8 Pg. 828-30 (Aug 2008) ISSN: 1099-0496 [Electronic] United States
• PMID: 18618617 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: (c) 2008 Wiley-Liss, Inc.

Chemical References

• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Administration, Inhalation
• Bronchoalveolar Lavage
• Child
• Combined Modality Therapy
• Female
• Granulocyte-Macrophage Colony-Stimulating Factor (administration & dosage, therapeutic use)
• Humans
• Pulmonary Alveolar Proteinosis (drug therapy, therapy)
• Treatment Outcome